Illumina Inc. stock gains on fresh collaboration and solid quarterly figures

Illumina Inc. stock (ISIN US4523271090) is currently supported by improved fundamentals and strategic partnerships, with the shares recently opening at USD 213.63 and sitting close to a 12 month high of USD 231.81 as of September 1, 2026, according to data compiled by MarketBeat.

Five year collaboration agreement boosts sentiment

On September 1, 2026, Novacyt announced that it had signed a five year collaboration framework agreement with Illumina, describing the company as a global leader in DNA sequencing and chip based technologies, which adds a new long term revenue opportunity for Illumina and reinforces its position in clinical diagnostics.

The collaboration is expected to link Novacyt’s assay development capabilities with Illumina’s sequencing platforms, giving Illumina an additional channel for consumables and instrument usage over the duration of the agreement and helping to underpin volume growth in its core sequencing business.

Recent earnings show revenue and profit growth

In its most recent reported quarter, Illumina delivered earnings per share of USD 1.31 and revenue of USD 1.16 billion, with revenue rising 9.4 percent year over year, according to MarketBeat data for the latest quarterly results.

The company has maintained its fiscal 2026 earnings per share guidance in a range of USD 5.30 to USD 5.40, signaling confidence that current momentum in sequencing demand and operational efficiencies can be sustained through the rest of the year.

Analyst view and valuation context

MarketBeat reports that institutional investors hold about 89.42 percent of Illumina’s shares, suggesting that the stock remains closely followed and largely owned by long term professional investors who can influence liquidity and price moves.

Despite the recent share price strength, the consensus analyst rating compiled by MarketBeat currently stands at Hold, with an average price target of USD 188.40, indicating that many analysts see limited upside from current levels and view the stock as fairly valued to slightly ahead of their central estimates.

For investors, the quantified revenue growth of 9.4 percent year over year to USD 1.16 billion and the maintained full year EPS guidance range provide the key benchmarks against which the current price around USD 213.63 and the 12 month high of USD 231.81 can be assessed.

NovaSeq X and sequencing platform economics

Illumina’s product portfolio is a central driver of its growth story, and in August 2026 the company highlighted the NovaSeq X series as its fastest and most cost efficient sequencing platform so far, capable of sequencing whole genomes at around USD 200 per genome, according to an overview by the Genetic Literacy Project.

This cost level, compared with earlier higher price points, underlines how Illumina is seeking to expand the addressable market for genomics by lowering per genome costs and increasing throughput, which can translate into higher instrument placements and recurring consumable revenue over time.

Illumina Inc. stock price and trading context

Based on recent quote data compiled by MarketBeat for NASDAQ listed Illumina, the stock opened at USD 213.63 and trades within a 12 month range between a low of USD 88.00 and a high of USD 231.81, giving investors a clear sense of the volatility and recovery the shares have experienced over the past year.